Brief: XOMA Earns $5 Million Milestone Upon FDA Acceptance Of Day One’s Tovorafenib NDA For Relapsed Or Progressive Pediatric Low-Grade Glioma (PLGG)

Xoma Royalty

31/10/2023 11:38

Oct 31 (Reuters) - XOMA Corp  XOMA.O :
    * XOMA EARNS $5 MILLION MILESTONE UPON FDA ACCEPTANCE OF DAY
ONE’S
TOVORAFENIB NDA FOR RELAPSED OR PROGRESSIVE PEDIATRIC LOW-GRADE
GLIOMA (PLGG)
    * XOMA CORP - FDA HAS GRANTED TOVORAFENIB PRIORITY REVIEW
AND
ESTABLISHED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE OF
APRIL 30, 2024

Source text for Eikon:  ID:nGNX9YhKpF 
Further company coverage:  XOMA.O